The objective is to integrate the leading leukemia trial groups (CML, AML, ALL, CLL, MDS, CMPD), their interdisciplinary partners (diagnostics, treatment research, registry, guidelines), industry and SMEs across Europe to form a cooperative network for advancements in leukemia-related research and health care.Integration will be supported by central information, communication, education and management structures. Other goals are to intensify target and drug discovery, to shorten the time period to clinical translation, to apply advanced genomics, telematics and biotechnology to therapeutic progress and to promote research relevant also for solid cancers by large clinical trials. Furthermore, metaanalyses of specific subaspects, elaboration of prognostic scores, recognition of gender specific differences, creation of uniform data sets for trials and registration, introduction of standards for diagnostics and treatment and development of evidence-based guidelines will be promoted throughout Europe. The proposed network will have the expertise and critical mass for European added value and world leadership. It will structure European research durably, spread European scientific excellence in the field of leukemias and can start immediately.